Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Vila Nova De Gaia – page 47

680 clinical trials in Vila Nova De Gaia, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Vila Nova De Gaia at a glance
680
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

680 trials in Vila Nova De Gaia

Open in trial search

Mantle cell lymphoma

Not recruiting

Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:BeOne Medicines AG

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Pirtobrutinib to Bendamustine and Rituximab for Untreated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Loxo Oncology Inc.

Osteogenesis imperfecta

Not recruiting

Study on Setrusumab for Patients with Osteogenesis Imperfecta (Brittle Bone Disease)

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Setrusumab
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Small cell lung cancer limited stage

Not recruiting

Study of Tarlatamab for Patients with Limited-Stage Small-Cell Lung Cancer After Chemoradiotherapy

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Amgen Inc.

Adenocarcinoma gastric

Not recruiting

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer After Trastuzumab Treatment

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Daiichi Sankyo Inc.

Non-small cell lung cancer

Not recruiting

Study of Immunotherapy Combinations with GSK4428859, Dostarlimab, and GSK6097608 for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study Comparing Crovalimab and Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently on Complement Inhibitors

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Crovalimab
  • Sponsor:F. Hoffmann-La Roche AG

Transitional cell carcinoma

Not recruiting

Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Pulmonary hypertension

Not recruiting

Study on the Effectiveness and Safety of Ralinepag for Patients with Pulmonary Arterial Hypertension

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ralinepag
  • Sponsor:United Therapeutics Corp.

Non-small cell lung cancer

Not recruiting

Study of Amivantamab and Lazertinib Combination vs. Osimertinib vs. Lazertinib for First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of Vutrisiran and Patisiran for Patients with Hereditary Transthyretin Amyloidosis

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Patisiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Eosinophilic granulomatosis with polyangiitis

Not recruiting

Study on the Effectiveness and Safety of Depemokimab vs. Mepolizumab for Adults with Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Portugal

The busiest research cities in the country

All 47 cities in Portugal

Clinical research in Vila Nova De Gaia

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on head and neck cancer, breast cancer, and multiple myeloma treatments. Studies include evaluations of novel therapies for both early-stage and metastatic conditions.

  • Advanced Head & Neck Squamous Cell Carcinoma
  • HER2-positive Breast Cancer
  • Multiple Myeloma Maintenance Therapy

Research encompasses targeted therapies and combination treatments aimed at improving patient outcomes.

02 Autoimmune Disorders

Comprehensive studies investigating treatments for various autoimmune conditions, including Sjögren's Syndrome and systemic sclerosis. Focus on developing targeted therapies for immune system regulation.

  • Primary Sjögren's Disease
  • Diffuse Cutaneous Systemic Sclerosis
  • Immune Thrombocytopenia

Evaluating novel biological therapies to address complex autoimmune manifestations.

03 Metabolic & Cardiovascular Studies

Research focused on obesity management and cardiovascular health. Studies evaluate new therapeutic approaches for weight management and cardiovascular disease prevention.

  • Obesity Treatment
  • Pulmonary Arterial Hypertension
  • Cardiovascular Risk Management

Investigating innovative treatments to address growing metabolic health challenges.

Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.